Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 3/20 | 0.47 |
| ▸ | TOP2A | P11388 | 2/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | POLR1A | O95602 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823899 | 0.87 | BRD4 (0.46) | RAD52ALDH1A1KDM4ERXFP1 | |
| SCHEMBL635319 | 0.86 | RAD52 (0.63) | RAD52UHRF1POLR1AALDH1A1CYP1A2 | |
| SCHEMBL632020 | 0.85 | CNR2 (0.39) | RAD52CNR2POLR1AALDH1A1CYP1A2 | |
| SCHEMBL634185 | 0.83 | KDM4E (0.46) | RAD52ALDH1A1KDM4ERXFP1 | |
| SCHEMBL634993 | 0.78 | TSHR (0.41) | RAD52TOP2AUHRF1POLR1AALDH1A1 | |
| SCHEMBL635676 | 0.78 | KDM4E (0.37) | CNR2POLR1AALDH1A1KDM4E | |
| SCHEMBL634175 | 0.76 | RAD52 (0.64) | RAD52UHRF1POLR1AALDH1A1CYP1A2 | |
| SCHEMBL634012 | 0.74 | KDM4E (0.40) | CNR2ALDH1A1KDM4E | |
| SCHEMBL634104 | 0.73 | POLR1A (0.50) | RAD52UHRF1POLR1AALDH1A1CYP1A2 | |
| SCHEMBL27624959 | 0.72 | RAD52 (0.72) | RAD52UHRF1POLR1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | claimed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | RAD52 2694/4885TOP2A 104/4885UHRF1 1983/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | RAD52 2746/4885TOP2A 107/4885UHRF1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.